NDAORALTABLET
Approved
Apr 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ESTROVIS (quinestrol) is an oral estrogen tablet approved in 1996 for hormone replacement therapy and related estrogen-deficiency indications. Quinestrol is a synthetic estrogen that mimics endogenous estrogen to alleviate menopausal symptoms and support bone health. The drug works through classical estrogen receptor binding to modulate gene expression in target tissues.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team likely faces declining headcount and reduced marketing investment as generic erosion accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ESTROVIS offers limited career growth due to its LOE stage and minimal linked job openings (0 identified). This role suits professionals seeking stability in a legacy product or those transitioning to value-based care and generic management strategies.
Brand ManagerField Sales Representative
Worked on ESTROVIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.